Main Menu

Novavax, Inc.


Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of Novavax, Inc. ("Novavax") on behalf of stockholders.  A class action complaint has been filed against Novavax, which alleges that defendants made a series of misrepresentations concerning Novavax's manufacturing capabilities and alignment with U.S. Food and Drug Administration ("FDA") criteria needed before filing its EUA for Novavax's vaccine candidate, NVX-CoV2373, with the FDA. Specifically, defendants made material misstatements and omissions including: (i) Novavax being aligned with FDA criteria while concealing multiple manufacturing problems, which included: (a) NVX-CoV2373 failing to meet certain FDA quality standards for purity and potency levels for its vaccine; (b) Novavax experienced rampant contamination outbreaks including both the Texas and North Carolina facilities; (c) Novavax was unable to successfully scale up production; and (d) all of which caused significant delays that jeopardized any chance Novavax had to capitalize on the market for Covid19 vaccines; and (ii) when Novavax ultimately had to delay its EUA filing, reassuring investors that Novavax resolved such manufacturing problems that caused the delay.

Join This Action

Alternatively, you may upload your transactions using the upload button below or email them to

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 04/23/2024

* Indicates a required field.

Back to Page